Douglas Thomson

Douglas Thomson is co-founder at Pneumagen and served as CEO from 2020 until 2026. His background is in infectious disease vaccine research and development. He was previously at SingVax, in Singapore, as CEO, and Microscience Ltd as Business Development Director. Douglas is a non-executive director of EnteroBiotix, a clinical stage microbiome therapeutics platform and product company, and Clarametyx Inc. a clinical phase company combating the formidable challenge of chronic respiratory diseases. He is also a Venture Partner with the KAMRA fund, which is focused on infectious disease.